Analyst Research Report Snapshot

Title:

Krka, d. d., Novo mesto

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

08 Apr 2014

Pages:

30

Type:

AcrobatPDF

Companies referenced:

KRKG.LJ

Available for Immediate Download
Summary:

Krka, d. d., Novo mesto - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on Krka, d. d., Novo mesto required for business and competitor intelligence needs - A study of the major internal and external factors affecting Krka, d. d., Novo mesto in the form of a SWOT analysis - An in-depth view of the business model of Krka, d. d., Novo mesto including a breakdown and examination of key business segments - Intelligence on Krka, d. d., Novo mesto’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Krka, d. d., Novo mesto, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Krka, d. d., Novo mesto (Krka or 'the group'), is a Slovenia-based provider of prescription pharmaceuticals, self-medication products, and animal health products. The group is also engaged in the health resort business and providing tourist services. The group primarily operates in Europe. It is headquartered in Novo Mesto, Slovenia and employed 9,461 people as of December 31, 2012. The group recorded revenues of E1,143.3 million ($1,470.1 million*) during the financial year ended December 2012 (FY2012), an increase of 6.3% over FY2011. The operating profit of the group was E192.3 million ($247.3 million*) during FY2012, a decrease of 9.1% compared with FY2011. The net profit was E159.9 million ($205.6 million*) in FY2012, a decrease of 1.8% compared with FY2011. *Calculated using the constant conversion rate of E1 = $1.2858 for the financial year ended December 31, 2012. Reasons to Purchase: - Gain understanding of Krka, d. d., Novo mesto and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Krka, d. d., Novo mesto as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Krka, d. d., Novo mesto’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.